Insmed: A blockbuster launch, priced ahead of its own guidance. Summary. * Insmed Incorporated is rated Hold, with a fair value of ~$99 versus a $110 share price, reflecting a blockbuster BRINSUPRI launch. * INSM's valuation assumes BRINSUPRI sustains ~$75M quarterly sales growth for three years, exceeding the company's Q4 midpoint guidance. * Key catalysts are Q4 2026 BRINSUPRI sales and the January 2027 FDA decision on ARIKAYCE's label expansion; either could shift the rating. * Rising costs, AstraZeneca royalties, and potential competition from Boehringer Ingelheim's rival pill are material risks to the investment thesis. Insmed Incorporated (INSM) has had a blockbuster launch with BRINSUPRI, its once-a-day pill, the only approved medicine for non-cystic fibrosis bronchiectasis (NCFB), according to Insmed, which entered the market in August 2025, but the current price of about $110 seems to be already paying for it to keep a fast pace, adding about $75 million of quarterly sales every quarter for three more years, which is faster than the midpoint of the company's own Q4 guidance. For Q3 2026, BRINSUPRI recorded sales of $400.1 million, up 29% from Q2. I believe that the next tests for the stock are the FDA decision on the wider ARIKAYCE label, which is due January 28, 2027, and the full-year 2026 results, which currently don't have a date announced but last year's was February 19. Either of these tests could tip my rating to a Sell, as it's a narrow Hold. An FDA refusal would tip my fair value to about $92, and a weak Q4 would move it down to about $74 at the guide's midpoint. Insmed and the BRINSUPRI Launch. For Q3 2026, the company had total sales of $524.4 million, and BRINSUPRI alone made up 76.3% of that at $400.1 million, so a lot rests on this one drug's launch. Insmed's accounting seems to assume about 14 years of exclusivity from the August 2025 US approval, which would carry it into 2039, but the main US patents on BRINSUPRI's drug substance expire on January 21, 2035, before any extension. The launch has been adding about $63 million to $101 million per quarter, about $85 million on average, and the question now is how long that momentum will last. The guidance has been raised twice, with the 2026 BRINSUPRI guidance going from "at least $1 billion" on February 19 to a range of $1.25 - $1.4 billion on August 6 and then $1.35 - $1.4 billion on October 29. A good record thus far, but the unchanged top does not go unnoticed, as Insmed decided not to raise its ceiling even after a strong Q3. As of 9M 2026, BRINSUPRI has sales totaling $917.1 million, so Q4 needs to bring in $432.9 million to $482.9 million, which would be an addition of $32.8 million to $82.8 million, with a midpoint of $57.8 million on Q3's $400.1 million. That midpoint is about a third smaller than the $90.9 million Q3 added, so the guidance only asks for a slower step, which is not unreasonable considering the drug's sales growth thus far. In fact, I believe this guidance may be a bit too cautious, which is why my own estimate in the Valuation section sits above its midpoint. By my calculations, H2 now needs $833 million to $883 million, and the August range implied $733 million to $883 million (with first-half sales of $517 million), so the October guide already puts H2 in the top third of what August allowed. Who else is paid. AstraZeneca PLC (AZN), which licensed brensocatib to Insmed, is owed tiered royalties "ranging from high single-digit to mid-teens" on net sales of BRINSUPRI. In Q3 2026, the cost of sales, which includes royalties, was 14.9% of sales, down from 20.6% in Q3 2025, but that is probably because some of the pills sold now were made before approval and their cost was booked earlier as research, so the 14.9% is more likely a temporary low rather than a normal level. For my valuation, I assumed an 18% cost of sales, but that's just my estimate and a judgment call. The two things which should push it up are AstraZeneca's higher tiers, whose thresholds are not disclosed, and the end of the pre-approval stock. ARIKAYCE And TPIP. Both are real chances, so I didn't value either at zero, with the ARIKAYCE label getting its spot in my numbers, and TPIP getting partial credit. ENCORE tested ARIKAYCE in newly diagnosed patients, whereas today's label only covers those whose infection resisted other antibiotics, and on March 23, 2026, it was announced that ENCORE Phase 3b met its primary endpoint with a respiratory symptom score of +17.77 points with ARIKAYCE vs. +14.66 without, a difference of 3.11 points (p=0.0299). A clear win but a modest gap in symptoms, so while a wider label is likely, the size of the sales gain is not. The filing for a wider ARIKAYCE label got accepted under priority review with a decision due on January 28, 2027. Today, ARIKAYCE may only be used in US patients whose infection did not clear on standard antibiotics, and its US sales are barely growing, with Q3 2026 US sales of $75.5 million, up 2% YoY, but the wider label could change that. Meanwhile, TPIP is Insmed's big pipeline drug, an inhaled once-a-day treatment for high blood pressure in the lungs, with three Phase 3 trials running and a fourth planned: * PALM-ILD has more than 35% enrolled, with enrollment due to finish in H1 2028, * PALM-PAH started July 2026, * PALM-PPF started September 2026, * An IPF trial is due to start in H1 2027. Naturally, the results can only come after a trial finished enrolling and treating patients, so not before 2028, and I would regard this to be the biggest unknown in the stock, and it is years away, so I gave it partial credit. Financials. The company is near break-even, but its costs are growing too, though I still expect profit to come. R&D spending went from $210 million in Q2 2026 to $270 million in Q3, up $60 million in just a quarter. Against Q3 2025, the company says the increase came mainly from manufacturing and clinical costs "primarily related to TPIP." In fact, Q3 2026 TPIP external R&D spending was $79.2 million, against $28.8 million a year earlier, and I expect costs to keep rising while the trials run. By my calculations, the company had an operating loss of $76.8 million for Q3 2026 (sales of $524.4 million - cost of sales $78.2 million - R&D $270 million - SG&A $253 million), before amortization and contingent-consideration changes, which include $41.2 million of stock pay, so the company is close to break-even, but as 2027 profit would still be small while it invests in TPIP, I wouldn't consider 2027 a fair year to value on. At September 30, 2026, Insmed had cash and investments of $1,146.6 million; however, if we remove the term loan $546.8 million, its 2% exit fee of $10.9 million, OrbiMed royalty financing of $156.5 million, the Motus acquisition obligation of $178.1 million, and AstraZeneca milestones due of $50 million, that brings the cash cushion to just $204.3 million. With that said, the company stated "We Continue to Believe Cash Flow Positivity in 2027 Can Be Achieved Without Additional Capital", assuming "no material expansion in expense base from business development," so it is believable on the current numbers, but it only holds if Insmed does not take on big new costs. Valuation. This section is based purely on my forecasted estimates. If BRINSUPRI adds $70 million, which sits between the guide's Q4 midpoint and its top, and below the $85.2 million average of the last three quarters since launches tend to add less as they mature, for every quarter from Q4 2026: for Q4 2026 that would be $470.1 million, and 2029 BRINSUPRI would be at $4,820.4 million, which is the figure that everything rests on, but it is entirely my estimate. Building on that, my further 2029 estimates are $4,820.4 million (BRINSUPRI) + $618.9 million (ARIKAYCE, +10% a year from $465 million, the midpoint of Insmed's $460 million to $470 million 2026 guidance) = $5,439.3 million, minus cost of sales at 18% ($979.1 million), R&D $1,300 million (Q3 x 4 = $1,080 million today), and SG&A $1,300 million (Q3 x 4 = $1,012 million today) = $1,860.2 million of operating profit, and after 24% tax that leaves $1,413.8 million as a forecasted profit after paying staff in shares and after tax, before interest. This assumes the cost of sales with the royalty tiers, the ARIKAYCE label is widened via FDA approval on the request, R&D rises for TPIP and the trials starting in 2027, and SG&A grows with sales and Japan. So, from near break-even today, if it keeps a pace of about $70 million adding on every quarter, I forecast the company to make about $1.4 billion of after-tax operating profit in 2029. And to put a value on that profit, I am using a required return of 10% a year, which, in my eyes, is fair to a company that depends this much on one young drug and has a rival in Phase 3. I also let the 2029 profit grow 8% a year from 2030 to 2038, which gives TPIP partial credit, and 2% a year after that, as I believe Insmed's research should largely replace BRINSUPRI's profit once its exclusivity ends. Brought back to today, the profit from 2029 onwards is worth about $21.3 billion. Adding the 2027 and 2028 profits ($1.1 billion, untaxed as the tax losses cover them), the net cash after other claims ($204.3 million), and the tax the remaining losses should save ($500 million, my estimate), and deducting $300 million of cash that growth ties up, brings me to around $22.8 billion, or $98.89 per share on 230.14 million diluted shares, which is about 10% below the $110 current share price. The table below demonstrates just how much of this depends on the launch pace and on profit growth after 2029. | BRINSUPRI added per quarter | 3% growth | 8% growth | 12% growth | | $50 million | $43.9 | $58.7 | $74.7 | | $70 million | $74 | $98.9 | $125.8 | | $90 million | $104 | $139 | $176.8 | So with a fair value of about $99, I believe a Hold is appropriate at this time, but even small changes could tip it to a Sell (which I will address in the Risks section). By my calculations, at the current $110 price, BRINSUPRI needs to add $75.5 million a quarter (2029 BRINSUPRI sales would be at $5,073.4 million) with 8% growth after. At the guide's midpoint of $57.8 million, the fair value would be about $74.4, and $124.6 at its top of $82.8 million - so the price is already assuming a pace which is closer to the top of the guidance. Of my $98.89 fair value, about $49.9 a share comes from profit after 2038; it rests on Insmed's research turning into new drugs that replace BRINSUPRI's sales, since that is the value of the years after BRINSUPRI's exclusivity is assumed to end. With no growth after 2038, the fair value would drop to about $88.1, and if that profit was halved, to about $68.6. Risks. My rating is a Hold until Q4 shows the pace. If Q4 2026 BRINSUPRI sales come in below about $467.4 million, I would likely downgrade my rating to Sell, or if it is above about $483.9 million, I would likely upgrade my rating to Buy. If Q4 2026's addition becomes the pace, a $90 million pace would give about $139 a share. Separately, an ARIKAYCE refusal (with flat sales) would drop it to about $92.2. The bulls' best argument for the stock is that the launch added $91 million to $101 million in each of the last two quarters, so it might just keep going. Insmed's long-range targets are indeed higher, but its only near-term number, the Q4 guidance, tops out at an $82.8 million step, and in my eyes launches usually add less each quarter as they mature. So for the current price to be fair, BRINSUPRI has to keep adding about $75.5 million a quarter for three more years, which is well above the midpoint of what the company itself guides today for Q4 - though not unrealistic. There's also Boehringer Ingelheim's rival pill BI 1291583, which works the same way as BRINSUPRI and is currently in Phase 3 (AIRTIVITY) with about 1,755 patients planned, currently still recruiting, with the same main measure as BRINSUPRI's trial and an estimated primary completion of June 15, 2027. I consider this to be the main outside risk, as, if it succeeds, BRINSUPRI would be facing a competitor from a large drug company within just a few years, though it is not a separate cut in my numbers but influenced my 8% growth. Conclusion. Summing it up, it's a real blockbuster launch, and guidance asks Q4 for about $58 million more, but AstraZeneca's cut rises as sales grow, and costs climb with TPIP. Hence, I rate the stock a Hold with a fair value of about $99 against $110, as even though the company is doing well, it seems that the price is already paying for it. Q4 sales in February would decide the next move. Gary Aquilina is an independent research analyst with a BA in Business Enterprise who has been analyzing stocks for personal knowledge since 2020. Over the years, he has taken a particular interest in the world of pharmaceuticals and biotech, looking to find deep value plays sitting outside the box, whilst also generally keeping an eye on macroeconomic and stock market trends, and fundamentals which shape their valuations, especially to spot undervalued picks.Closely associated with Jordan Aquilina. Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Insmed (NasdaqGS: INSM) has launched BRINSUPRI tablets in Japan for non cystic fibrosis bronchiectasis. The company describes it as the first approved therapy in Japan for the condition, covering adults and adolescents. The launch gives Insmed access to patients who previously had no targeted treatment. It also helps diversify revenue beyond the US. Insmed also made regulatory progress for ARIKAYCE, an inhaled therapy, as it works toward broader use. The company has raised its 2026 guidance to $1.35 billion to $1.4 billion for BRINSUPRI and $460 million to $470 million for ARIKAYCE. Investors will watch how sales track against those ranges, and for updates on the ARIKAYCE supplemental filing review.